Mesothelioma: No Cure Yet, But Much Promise in New TherapiesMary Hesdorffer
Making Cents of Mesothelioma Katie Kosko December 14th 2020 A new grant program offers financial assistance for patients with mesothelioma who must travel for cancer care. Read More CancerCare Celebrates 75 Years of Serving the Cancer Community ...
Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Novocure has several additional ongoing or completed clinical trials exploring the use of Tumor ...
The LUNAR study is a pivotal, open-label, randomized study evaluating the safety and efficacy of Tumor Treating Fields (TTFields) together with standard therapies for stage 4 non-small cell lung cancer (NSCLC) following progression while on or after treatment with platinum-based therapy. The ...
In light of the success of T-cell checkpoint inhibitor therapy in advanced lung cancer, these drugs are now being tested in the treatment of locally advanced NSCLC. Recently, a phase 3 study of adjuvant durvalumab (anti-PD-L1) in patients with stage III NSCLC without progression immediately af...
December 19, 2024 · 1 min read · Annalee Armstrong Manufacturing Novo Deepens Denmark Commitment With $1.2B Rare Disease Production Facility December 16, 2024 · 2 min read · Tristan Manalac Mergers & acquisitions Novo Holdings Gets FTC’s Go-Ahead f...
There is a very good explanation for why cancer research has failed so badly… It has been directed away from the true main cause of most cancer – toxins. In early years, such misdirection could be partially explained by the lack of understanding about the nature and causes of cancer. In...
CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of the cancer experience.
for stage IV non-small cell lung cancer in our Lunar trial. In collaboration with Merck, we will expand our research in lung cancer to study the combination of tumor treating fields concomitant with Keytruda for first-line treatment of Stage III non-small cell lung cancer and a Phase 2 ...
therapies alone. The LUNAR study is a pivotal, open-label, randomized study evaluating the safety and efficacy of Tumor Treating Fields (TTFields) together with standard therapies for stage 4 non-small cell lung cancer (NSCLC) following progression while on or after tre...